Market Cap : 2.21 B | Enterprise Value : 2.22 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics's change in receivables for the quarter that ended in Mar. 2022 was $-28.4 Mil. It means PTC Therapeutics's Accounts Receivable increased by $28.4 Mil from Dec. 2021 to Mar. 2022 .
PTC Therapeutics's change in receivables for the fiscal year that ended in Dec. 2021 was $-45.0 Mil. It means PTC Therapeutics's Accounts Receivable increased by $45.0 Mil from Dec. 2020 to Dec. 2021 .
PTC Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2022 was $141.3 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PTC Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2022 was 86.68.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PTC Therapeutics's liquidation value for the three months ended in Mar. 2022 was $-1,188.8 Mil.
The historical data trend for PTC Therapeutics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
PTC Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 141.288 | / | 148.735 | * | 91 |
= | 86.68 |
2. In Ben Graham's calculation of liquidation value, PTC Therapeutics's accounts receivable are only considered to be worth 75% of book value:
PTC Therapeutics's liquidation value for the quarter that ended in Mar. 2022 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 587.793 | - | 1890.172 | + | 0.75 * 141.288 | + | 0.5 * 15.281 |
= | -1,188.8 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of PTC Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Seekingalpha 2020-10-30
By Zacks 2020-08-27
By Seekingalpha 2022-02-23
By Zacks 2021-05-27
By Zacks 2020-08-18
By Seekingalpha 2021-01-23
By Seekingalpha 2021-02-26
By Zacks 2022-04-04
By Seekingalpha 2021-01-20
By Zacks 2021-02-25
By Zacks 2021-05-04